# OnCo record pancreatic-failed-programmes (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/pancreatic-failed-programmes/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "pancreatic-failed-programmes" ;
  schema:name "Pancreatic cancer: the failed and stopped programmes and why"@en ;
  schema:alternateName "Negative pancreatic cancer trials"@en, "Pancreatic cancer phase 3 failures"@en ;
  schema:description "Pancreatic cancer has a long list of phase 3 trials that added a new drug to standard chemotherapy and found nothing: a stroma-degrading enzyme, an interleukin-10, a stemness inhibitor, a BTK inhibitor, a metabolic inhibitor, an anti-fibrotic antibody, two vaccines and erlotinib in three settings. Radiotherapy after chemotherapy improved local control but not survival."@en ;
  schema:url <https://onco.cc/terms/pancreatic-failed-programmes/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.20.00590>, <https://doi.org/10.1200/JCO.20.02232>, <https://doi.org/10.1016/j.eclinm.2023.101897>, <https://doi.org/10.1016/j.annonc.2021.01.070>, <https://doi.org/10.1200/JCO.2017.72.6463>, <https://doi.org/10.1097/COC.0000000000000633>, <https://doi.org/10.1056/NEJMoa032295>, <https://doi.org/10.1200/JCO.2016.68.5776>, <https://doi.org/10.1158/1078-0432.CCR-18-2992>, <https://clinicaltrials.gov/study/NCT05737706> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/locally-advanced-pdac/>, <https://onco.cc/cancers/resectable-pdac/> ;
  onco:drugs <https://onco.cc/drugs/pegvorhyaluronidase-alfa/>, <https://onco.cc/drugs/pamrevlumab/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/pegilodecakin/>, <https://onco.cc/drugs/algenpantucel-l/>, <https://onco.cc/drugs/eli-002-7p/>, <https://onco.cc/drugs/napabucasin/>, <https://onco.cc/drugs/devimistat/>, <https://onco.cc/drugs/eryaspase/>, <https://onco.cc/drugs/erlotinib/>, <https://onco.cc/drugs/mrtx1133/>, <https://onco.cc/drugs/folfox/> ;
  onco:terms <https://onco.cc/terms/desmoplasia/>, <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/terms/hazard-ratio/> ;
  onco:trials <https://onco.cc/trials/halo-301/>, <https://onco.cc/trials/lapis-trial/>, <https://onco.cc/trials/resolve/>, <https://onco.cc/trials/sequoia/>, <https://onco.cc/trials/eclipse/>, <https://onco.cc/trials/impress-trial/>, <https://onco.cc/trials/amplify-7p/>, <https://onco.cc/trials/canstem111p/>, <https://onco.cc/trials/avenger-500/>, <https://onco.cc/trials/trybeca-1/>, <https://onco.cc/trials/conko-005/>, <https://onco.cc/trials/lap07/>, <https://onco.cc/trials/conko-007/>, <https://onco.cc/trials/alliance-a021501/>, <https://onco.cc/trials/conko-003/>, <https://onco.cc/trials/norpact-1/>, <https://onco.cc/trials/preopanc-2/>, <https://onco.cc/trials/apact/>, <https://onco.cc/trials/nct05737706/> .